He is not paid in shares. Also, this is just his side gig.
Regarding Shire, the clue is in why they did a phase Ib and what the pharmacology results were. When they said there was no clinical difference it said it all. It's not dead yet, but the trial was a waste.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.